Deliconstantinos G, Barton S, Soloviev M, Page N. Mouse Hemokinin-1 Decapeptide Subjected to a Brain-specific Post-translational Modification.
ACTA ACUST UNITED AC 2017;
31:991-998. [PMID:
28882971 DOI:
10.21873/invivo.11159]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2017] [Revised: 08/03/2017] [Accepted: 08/04/2017] [Indexed: 11/10/2022]
Abstract
BACKGROUND/AIM
The tachykinin mouse hemokinin-1, expressed by the mouse Tac4 gene, produces either analgesia or nociception, interacting with the neurokinin 1 receptor. TAC4 precursor processing is not identical to the processing of the TAC1 precursor, for the release of substance P (amidated undecapeptide). The characterization of the mouse hemokinin-1 sequence was required.
MATERIALS AND METHODS
We developed anti-tachykinin-specific antibodies for the immunoaffinity purification of tachykinins.
RESULTS
Using MALDI-ToF, we identified mouse hemokinin-1 as an amidated decapeptide expressed in murine brain and periphery. Furthermore, we interestingly observed an additional mass peak corresponding to acetylated mouse hemokinin-1 and this post-translational modification is brain-specific, not detected in the periphery.
CONCLUSION
We suggest that the N-terminal acetylation of the peptide provides greater potency for ligand-receptor interactions during neural cell signaling.
Collapse